Posts filtered by tags: KRAS[x]


 

Immunotherapy alone extended life for metastatic lung cancer patients with KRAS mutation

Real-word evidence is suggesting, for the first time, the most beneficial treatment courses that could help extend the lives of patients with metastatic non-small cell lung cancer.
Tags: Science, KRAS


Mutant KRAS and P53 promote growth and metastasis of pancreatic cancer

Researchers at The University of Texas MD Anderson Cancer Center have discovered that mutant KRAS and p53, the most frequently mutated genes in pancreatic cancer, interact through the CREB1 protein to promote metastasis and tumor growth.
Tags: Health, The University of Texas MD Anderson Cancer Center, KRAS


Mutant KRAS and p53 cooperate to drive pancreatic cancer metastasis

MD Anderson researchers have discovered that mutant KRAS and p53, the most frequently mutated genes in pancreatic cancer, interact to promote metastasis and tumor growth. The findings point to a new therapeutic target for this deadly cancer.
Tags: Science, Anderson, KRAS


Study reveals new mutations that make cancer resistant to KRAS-targeted therapies

A gene called KRAS is one of the most commonly mutated genes in all human cancers, and targeted drugs that inhibit the protein expressed by mutated KRAS have shown promising results in clinical trials, with potential approvals by the U.S. Food and Drug Administration anticipated later this year.
Tags: Health, U S Food and Drug Administration, KRAS


Scientists uncover mutations that make cancer resistant to therapies targeting KRAS

Cancer drugs that inhibit the protein expressed by a mutated form of the KRAS gene might be approved later this year, but cancer cells often develop additional mutations that make them resistant to such targeted drugs. Investigators have identified some of these mutations in a patient and identified strategies to overcome them.
Tags: Science, KRAS


Study: Lowering the activity of KRAS gene can help fight pancreatic cancer

If clinicians could stop mutations of the KRAS gene in pancreatic cancer – which happens in more than 90 percent of pancreatic cancer cases and drastically reduces response to immunotherapy – the chances of improving treatment for this deadly form of cancer would be increased.
Tags: Health, KRAS


Lung cancer cells activate different signaling pathways in response to KRAS inhibitors

Genetic alterations of the KRAS gene are some of the most common mutations in lung cancer patients, but unfortunately these patients have few effective treatment options.
Tags: Health, KRAS


Lung cancer cells have differential signaling responses to KRAS inhibitor treatment

In a new article published in Clinical Cancer Research, Moffitt Cancer Center researchers show that various subtypes of lung cancer cells activate different signaling pathways in response to KRASG12C inhibitor treatment. These results may help identify potential combination therapy approaches and guide treatment decisions for lung cancer patients in the future.
Tags: Science, KRAS, Clinical Cancer Research Moffitt Cancer Center


MD Anderson and Mirati Therapeutics collaborate to expand evaluation of potent KRAS inhibitors

The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. today announced a strategic research and development collaboration to expand the evaluation of Mirati's two investigational small molecules, potent and selective KRAS inhibitors - adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in preclinical development, as monotherapy and in combination with other agents - which target two of the most frequent KRAS mutations in cancer.
Tags: Health, Anderson, University of Texas MD Anderson Cancer Center, KRAS, Mirati, Mirati Therapeutics Inc, Mirati Therapeutics


Sotorasib provides durable clinical benefit for patients with NSCLC and KRAS mutations

In the phase II CodeBreak 100 trial, sotorasib provided durable clinical benefit with a favorable safety profile in patients with pretreated non-small cell lung cancer (NSCLC) and who harbor KRAS p.G12C mutations, validating CodeBreak 100’s phase I results, according to research presented today at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.
Tags: Science, NSCLC, KRAS, International Association


Researchers uncover a potential treatment for an aggressive form of lung cancer

DALLAS - Jan. 5, 2021 - Researchers at the Children's Medical Center Research Institute at UT Southwestern (CRI) have discovered a new metabolic vulnerability in a highly aggressive form of non-small cell lung cancer (NSCLC). These findings could pave the way for new treatments for patients with mutations in two key genes - KRAS and LKB1. Patients whose tumors contain both of these mutations, known as KL tumors, have poor outcomes and usually do not respond to immunotherapy.
Tags: Science, Dallas, KRAS, Children s Medical Center Research Institute, UT Southwestern CRI


Inhibitor of KRAS gene mutation shows promise in lung, bowel and other solid tumors

New results from a clinical trial of a drug that targets a cancer-causing mutation in the KRAS gene have shown that it can shrink tumours and is well-tolerated by patients. In two presentations to the 32nd EORTC-NCI-AACR cancer symposium, researchers involved in the KRYSTAL-1 phase I/II clinical trial said that adagrasib (MRTX849) showed clinical activity and manageable adverse side effects in patients with non-small cell lung cancer, colorectal cancer and other solid tumours.
Tags: Science, Krystal, KRAS


Targeted inhibitor of mutated KRAS gene shows promise in lung, bowel, & other solid tumors

A novel agent that targets a mutated form of the KRAS gene - the most commonly altered oncogene in human cancers and one long considered "undruggable" - shrank tumors in most patients in a clinical trial with manageable side effects, researchers reported today at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Therapeutic, which is taking place online.
Tags: Science, KRAS, NCI


Vaccine to treat and prevent lung, bowel and pancreatic cancer shows promise in the lab

An experimental vaccine, designed to enlist the body's own immune system to target cancer cells, has shown promise for treating and preventing cancer in mice. The vaccine was created to target a gene called KRAS that is involved in the development of many types of cancer, including lung, bowel and pancreatic cancer.
Tags: Science, KRAS


Oncotarget: Exosomal lncRNA PCAT-1 promotes Kras-associated chemoresistance

Oncotarget Volume 11, Issue 29 reported that Immunosuppressive chemoresistance is a major burden in lung cancer.
Tags: Science, KRAS


KRASG12C inhibitor sotorasib shows durable clinical benefits for solid cancers

In a Phase I clinical trial for patients with advanced solid cancers marked by KRAS G12C mutations, the KRASG12C inhibitor sotorasib (AMG 510) resulted in manageable toxicities and durable clinical benefits.
Tags: Health, KRAS


KRAS inhibitor sotorasib appears safe, achieves durable clinical benefit in early trial

For patients with advanced solid cancers and KRAS G12C mutations, the targeted therapy sotorasib, a KRAS G12C inhibitor, resulted in manageable toxicities and durable clinical benefits, particularly in lung and colorectal cancer, in Phase I study.
Tags: Science, KRAS


Promising phase 1 trial results: Use of sotorasib (AMG 510) in patients with solid tumors

A phase 1 clinical trial of sotorasib (AMG 510) in patients with heavily pretreated advanced solid tumors shows encouraging anti-cancer activity, especially in lung and colorectal cancers, reports a new study led by City of Hope and other renowned comprehensive cancer centers. 'KRAS mutations have been linked with worse treatment outcomes in a variety of cancers,' Dr. Marwan Fakih said. 'This study has, in some cases, demonstrated a median progression-free survival that is two times longer than ...
Tags: Science, KRAS, Marwan Fakih


CNIO researchers develop an effective strategy against KRAS mutant lung tumors in mice

Researchers achieved complete remission of 25% of lung tumours caused by the KRAS oncogene in mice by inactivating CDK4 and RAF1, two genes that act at different levels in the signalling pathway of this oncogene. In addition, this therapeutic combination slows tumour growth in 100% of the cases. In spite of the high heterogeneity of these tumours, the team has managed to identify and therapeutically treat the different resistance mechanisms that can develop after inactivating both targets.
Tags: Science, KRAS, CNIO


Cancer-causing mutation also promotes inflammation

Analyses of cell signals provide insight into the origin of severe inflammatory symptoms that appear in various types of blood cancer and point to possible therapeutic approaches: In around one-fourth of patients suffering from juvenile myelomonocytic leukemia, there is evidence of mutations in the so-called KRAS gene in the leukemia cells.
Tags: Health, KRAS


Creating new drugs is too slow and too expensive. A top exec at the $130 billion biotech Amgen shares how he's 'loading the dice' to juice the chances of success

The business of developing new drugs faces two "existential challenges," Amgen's research chief David Reese told Business Insider in a recent interview. Those are: How long it takes to take a drug from idea to approval, and the high failure rates for therapies that start human trials, said Reese. He took charge of the $130 billion biotech's research strategy in 2018. "It has to change, therefore it will," Reese said on the low success rate of drugs, where about 8% that enter clinical testing a...
Tags: Utah, UK, Colorado, California, America, Trends, Deloitte, Jeff Bezos, Business Insider, Amg, Bush, Amgen, GSK, Reese, KRAS, Gilead


The man in charge of discovering new drugs at the world's biggest biotech told us how Amgen's 'triple threat' genetics approach can overcome the industry's high failure rates

The business of developing new drugs faces two "existential challenges," Amgen's research chief David Reese told Business Insider in a recent interview. Those are: How long it takes to take a drug from idea to approval, and the high failure rates for therapies that start human trials, said Reese. He took charge of the $130 billion biotech's research strategy in 2018. "It has to change, therefore it will," Reese said on the low success rate of drugs, where about 8% that enter clinical testing a...
Tags: Utah, UK, Colorado, California, Trends, Deloitte, Jeff Bezos, Business Insider, Amg, Bush, Amgen, GSK, Reese, KRAS, Gilead, Trump Obama


Overall survival in patients with lung adenocarcinoma harboring 'niche' mutations

Mutations were observed in all genes studied, except c-MET, DDR2, MAP2K1, and RET.The multivariable analysis showed that:Niche mutations had higher mortality than EGFR mutationsKRAS mutations had higher mortality than EGFR mutations, andNiche mutations presented similar mortality to KRAS mutations.
Tags: Science, EGFR, KRAS


Merck Ramps Up KRAS Chase Through Licensing Deal With Taiho, Astex

The KRAS gene has become a hot target for cancer research for a growing number of drug developers. Merck, which is already testing a KRAS vaccine candidate, is now spreading its bets with a licensing deal for small molecule KRAS drugs being developed by two Otsuka Pharmaceutical subsidiaries.Merck (NYSE: MRK) is paying $25 million up front for global rights to the preclinical compounds from the Otsuka companies, Taiho Pharmaceutical and Astex Pharmaceuticals. According to the deal terms, the ph...
Tags: Deals, New York, Trends, Merck, Colorectal Cancer, Immunotherapy, Biotech, Pancreatic Cancer, Life Sciences, Clinical Trials, Amgen, Sanofi, National Cancer Institute, KRAS, Eli Lilly, REVOLUTION Medicines


Science snapshots from Berkeley Lab

This edition of Science Snapshots highlights an investigational cancer drug that targets tumors caused by mutations in the KRAS gene, a new library of artificial proteins that could accelerate the design of new materials, and the natural toughening mechanism behind adult tooth enamel.
Tags: Science, Berkeley Lab, KRAS


Science snapshots

This edition of Science Snapshots highlights an investigational cancer drug that targets tumors caused by mutations in the KRAS gene, a new library of artificial proteins that could accelerate the design of new materials, and the natural toughening mechanism behind adult tooth enamel.
Tags: Science, KRAS


Here's Why Mirati Therapeutics Is Surging Today

Lackluster results from Amgen's KRAS inhibitor program are clearing a path for Mirati's candidate.
Tags: Science, Amgen, KRAS


Conquering cancer's infamous KRAS mutation

Scientists from Sanford Burnham Prebys and PHusis Therapeutics have shown that a compound called PHT-7.3 shrinks KRAS-driven tumors in mice. In contrast to directly targeting mutant KRAS, the potential drug candidate targets the protein's partner in crime: the cellular scaffold to which mutated KRAS attaches. The study was published in Cancer Research.
Tags: Science, KRAS, Sanford Burnham Prebys, PHT, PHusis Therapeutics


Scientists are working on cancer treatments that attack the disease's 'Holy Grail.' Big pharma and biotechs have already invested more than $1 billion.

A new technology could revolutionize how everything from Alzheimer's disease to autoimmune diseases and cancer are treated. Cancer has become an early focus for the technology, called targeted protein degradation or PROTAC, because there are many well-known drivers of cancer that modern medicine hasn't been able to reach.  At least $1 billion has been invested in the space by big pharmaceutical companies like Novartis and GlaxoSmithKline and biotech startups alike, one expert estimates.  Visit...
Tags: Trends, Yale, Connecticut, Fda, GlaxoSmithKline, Novartis, American Cancer Society, KRAS, Boehringer Ingelheim, Craig Crews, Ian Taylor, Tallarico, Novartis Institutes for BioMedical Research, TEEL, Lilly Ventures, Arvinas


EMV Capital takes controlling stake in Vortex Biosciences

EMV Capital has acquired a controlling stake in Vortex Biosciences, a provider of liquid biopsy of circulating tumor cells. No financial terms were disclosed. PRESS RELEASE LONDON (PRWEB) APRIL 25, 2019 Today EMV Capital announces the acquisition of a controlling stake in Bay Area-based Vortex Biosciences, and a further investment package to accelerate the company’s development. Robert Englert, CEO of Vortex Biosciences, commented “We will apply this new funding to achieve an expanded menu of do...
Tags: London, US, Trends, Healthcare, Ucla, Bay Area, Liu, CTC, KRAS, PE Deals, PRWEB, Europe Israel, VTX, Ilian Iliev, Renier, EMVC